JIN Yang Pharmaceutical진양제약
007370 · KOSDAQ · ₩007370 · 진양제약
₩3,405▼ ₩50 (1.45%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 66.0% | 64.8% | 61.7% | 61.1% | 59.9% | 54.1% |
| Operating margin | 3.0% | 2.1% | 10.3% | 9.7% | 14.6% | 11.1% |
| Net margin | 18.3% | 18.5% | 26.2% | 13.5% | 16.1% | 15.2% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +3.3% | +6.5% | +20.4% | +23.4% | +21.4% | — |
| Operating income growth | +50.0% | −78.4% | +28.9% | −18.4% | +60.0% | — |
| Net income growth | +2.3% | −24.9% | +134.6% | +2.8% | +29.1% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 14.2% | 15.9% | 28.4% | 15.1% | 17.2% | 14.6% |
| Return on assets | 8.4% | 9.0% | 17.1% | 10.8% | 11.6% | 9.7% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 69.2% | 67.5% | 89.8% | 33.8% | 47.5% | 50.8% |
| Net debt to equity | −2.4% | −3.0% | 64.5% | 1.7% | 9.4% | −9.3% |
| Current ratio | 52.0% | 52.3% | 219.0% | 195.9% | 149.7% | 151.1% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: JIN Yang Pharmaceutical / 진양제약 / 007370 / KRX:007370
Source: KRX statistical information